TheraRadar
← Back
Data updated: Jun 28, 2026

HORIZON

Specialty
Pharmaceuticals

HORIZON is a specialty pharmaceutical company with 5 FDA-approved products.

2010
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

HORIZON's Key Drugs

HORIZON's core commercial portfolio centers on PROCYSBI — its most strategically important drugs approved in the last 15 years.

HORIZON's Recent FDA Approvals

New NDA/BLA approvals for HORIZON over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HORIZON's Therapeutic Areas

Disease areas where HORIZON has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

HORIZON Pipeline Snapshot

Active clinical trials for HORIZON across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • PROCYSBI leads revenue
  • Drug-level revenue analysis
View revenue breakdown →

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis
View patent timeline →

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Compare with competitor →
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling